Precigen Inc. has announced the FDA approval of PAPZIMEOS, a groundbreaking therapy for adult patients with Recurrent Respiratory Papillomatosis (RRP). This historic approval marks a significant milestone for the RRP community, offering a new FDA-approved treatment option that has the potential to reduce or eliminate the need for repeated surgeries. The approval was based on data from a pivotal study led by Clint T. Allen, MD, and Scott M. Norberg, DO, at the National Institutes of Health, which successfully met its primary safety and efficacy endpoints. Precigen will begin promoting PAPZIMEOS immediately and has established Papzimeos SUPPORT, a comprehensive patient support program. A conference call will be held on August 18 to provide further details regarding the approval.